Cells with improved inward rectifier current
OwnerL. Lee Lochbaum Eckhardt, Ravi Vaidyanathaninventors
Life of this patent
Estimating the term…
Abstract
Provided herein is technology relating to differentiated stem cells and particularly, but not exclusively, to stem-cell derived cardiomyocytes having improved inward rectifier currents (e.g., IK1 currents), methods for producing stem-cell derived cardiomyocytes having inward rectifier currents, and systems and uses related to stem-cell derived cardiomyocytes having enhanced inward rectifier currents.
Claims34
A stem cell derived cardiomyocyte comprising a nucleic acid encoding an inducible potassium inward rectifier channel.
A stem cell derived cardiomyocyte comprising an inducible potassium inward rectifier current (IK1).
A method of producing a physiologically mature stem cell derived cardiomyocyte, the method comprising:
- a) providing a stem cell derived cardiomyocyte comprising a nucleic acid encoding an inducible potassium inward rectifier channel;
- and
- b) inducing expression of said inducible potassium inward rectifier channel in said stem cell derived cardiomyocyte.
A system for testing the cardiac safety of a drug, the system comprising:
- i) a stem cell derived cardiomyocyte expressing a potassium inward rectifier channel;
- and
- ii) a cellular electrophysiology measurement system.
A cell expressing an inducible potassium inward rectifier channel.
A composition comprising a cell expressing an inducible potassium inward rectifier channel.
A method for testing a compound for cardiac safety, the method comprising:
- a) providing a physiologically mature stem cell derived cardiomyocyte comprising a nucleic acid encoding an inducible potassium inward rectifier channel;
- b) contacting said physiologically mature stem cell derived cardiomyocyte with a test compound;
- and
- c) measuring a physiological phenotype of said physiologically mature stem cell derived cardiomyocyte.
Dependencies are inferred from the claim text.